Orthocell has received regulatory approval from the Hong Kong Department of Health's Medical Device Division to commence sales of Remplir™ in the Hong Kong nerve repair market.
Read more
Orthocell has appointed 12 US distributors for its nerve repair product Remplir™, well ahead of the expected target of 10 distributors by 30 June.
Read more
Orthocell has secured a Medical Device Licence from Health Canada for Remplir™, opening access to the US$75 million Canadian nerve repair market.
Read more
Orthocell has been granted a licence by the Food and Drug Administration of Thailand to commence sales of Remplir™ into the significant and growing US$84 million Thai nerve repair market.
Read more
Orthocell has appointed four US distributors for its flagship nerve repair product Remplir™, enabling the commencement of commercial distribution into the US.
Read more
Orthocell has announced that it has appointed Device Technologies Asia as the exclusive distributor of market leading peripheral nerve repair device Remplir™ in Singapore.
Read more
In this episode of Orthocell’s ‘Meet the Board’ video series, we feature Independent Director, Dr. Ravi Thadhani.
Read more
Orthocell has today reached another significant milestone with the successful completion of its Remplir™ 510(k) nerve repair regulatory study, validating Remplir as a safe and effective biological medical device for use in the surgical repair of peripheral nerves.
Read more
Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory and reimbursement strategies for its nerve repair device, Remplir.
Read more
Orthocell’s recent FDA clearance made headlines on 7 News this week, with journalist Alice Murray showcasing the human impact of our nerve repair technology.
Read more
Orthocell welcomed 9 News journalist Michael Stamp to Orthocell HQ last week to film an in-depth segment about our FDA clearance for the nightly news.
Read more